Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.

STUDY OBJECTIVES The objectives of the study were as follows: (1) to identify differences in endothelial dysfunction and altered hemostasis in patients with chronic thromboembolic pulmonary hypertension (CTEPH) compared with patients with acute pulmonary thromboembolism (APTE) uncomplicated by pulmonary arterial hypertension, by measuring the concentrations of thrombomodulin (TM), a receptor for thrombin and a major anticoagulant proteoglycan on the endothelial membrane, and other plasma factors of coagulation and fibrinolysis; and (2) to examine the effects of thromboendarterectomy on TM levels as a parameter of endothelial cell injury leading to abnormal hemostasis as well as to examine the clinical significance of TM as a marker of endothelial injury. DESIGN Prospective comparison of concentrations of TM and other plasma parameters among patients with CTEPH or APTE and control subjects. PARTICIPANTS We studied 22 healthy subjects (ie, control subjects), 22 patients who had been clinically stabilized after APTE, and 44 patients with CTEPH. In 21 of the patients with CTEPH, measurements were repeated after they had undergone pulmonary thromboendarterectomy. MEASUREMENTS AND RESULTS Plasma concentrations of soluble TM in patients with CTEPH were measured and compared with those in patients with APTE. The mean (+/- SD) TM concentration in the CTEPH group (2.5 +/- 0.7 ng/mL) was significantly lower than that in the control group (4.0 +/- 0.6 ng/mL; p < 0.05). In contrast, the mean plasma TM concentration in the APTE group (4.6 +/- 1.9 ng/mL) was similar to that in the control group. After patients underwent pulmonary thromboendarterectomy, the mean TM concentration increased from 2.0 +/- 0.4 to 2.9 +/- 0.7 ng/mL (p < 0.05). In the CTEPH group, the plasma TM concentration was negatively correlated with mean pulmonary arterial pressure and total pulmonary resistance (p < 0.05). CONCLUSIONS A decreased plasma TM concentration may reflect pulmonary vascular endothelial dysfunction leading to altered anticoagulant and fibrinolytic function in CTEPH, which rarely develops after APTE. Plasma TM measurements may be useful in distinguishing CTEPH with severe pulmonary hypertension from recurrent APTE.

[1]  Robert O. Bonow,et al.  Heart Disease: A Textbook of Cardiovascular Medicine. 7th Edition , 2004 .

[2]  F. Sakamaki,et al.  Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy , 2000, Circulation.

[3]  G. Simonneau,et al.  Thrombotic risk factors in pulmonary hypertension. , 2000, The European respiratory journal.

[4]  K. Kerr,et al.  Reoperative pulmonary thromboendarterectomy. , 1999, The Annals of thoracic surgery.

[5]  K. Kerr,et al.  Long-term outcome after pulmonary thromboendarterectomy. , 1999, American journal of respiratory and critical care medicine.

[6]  S. Arcasoy,et al.  Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. , 1999, Chest.

[7]  K. Hassell,et al.  Altered hemostasis in pulmonary hypertension. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[8]  R. Barst,et al.  Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. , 1997, Circulation.

[9]  R. Marlar,et al.  Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. , 1996, Chest.

[10]  J. Piette,et al.  Plasma levels of thrombomodulin in pulmonary hypertension. , 1996, The American journal of medicine.

[11]  G. Simonneau,et al.  Continuous Infusion of Prostacyclin Decreases Plasma Levels of t-PA and PAI-1 in Primary Pulmonary Hypertension , 1995, Thrombosis and Haemostasis.

[12]  J. Amiral,et al.  Membrane thrombomodulin levels are decreased during hypoxia and restored by cAMP and IBMX. , 1995, Thrombosis research.

[13]  M. Olman,et al.  Parallel Analysis of Tissue‐Type Plasminogen Activator and Type 1 Plasminogen Activator Inhibitor in Plasma and Endothelial Cells Derived From Patients With Chronic Pulmonary Thromboemboli , 1994, Circulation.

[14]  J. Amiral,et al.  Levels of plasma thrombomodulin are increased in atheromatous arterial disease. , 1993, Thrombosis research.

[15]  Y. Ikeda,et al.  Soluble P‐selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome , 1993, British journal of haematology.

[16]  R. Tarazi,et al.  Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. , 1993, The Journal of thoracic and cardiovascular surgery.

[17]  K. Peterson,et al.  Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. , 1992, Radiology.

[18]  T. Hayashi,et al.  One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[19]  S. Kimura,et al.  Plasma thrombomodulin in health and diseases. , 1990, Blood.

[20]  W. Auger,et al.  Chronic major-vessel thromboembolic pulmonary hypertension. , 1990, Circulation.

[21]  J. Brody,et al.  Abnormalities of thrombomodulin and tissue plasminogen activator in occluded aortocoronary grafts detected by immunohistochemistry. , 1988, Transactions of the Association of American Physicians.

[22]  J. S. Bower,et al.  Partial reversibility of chronic pulmonary hypertension caused by pulmonary thromboembolic disease. , 1981, The American review of respiratory disease.

[23]  C. Esmon,et al.  Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. , 1981, The Journal of biological chemistry.